Burden of SARS-CoV-2 infection prior to vaccine eligibility among immunocompromised children aged 1-11 years at a pediatric tertiary referral hospital in Toronto, Canada.
COVID‐19
SARS‐CoV‐2
immunocompromised host
pediatrics
public health
seroepidemiological studies
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
revised:
29
08
2024
received:
31
07
2024
accepted:
23
09
2024
medline:
5
10
2024
pubmed:
5
10
2024
entrez:
5
10
2024
Statut:
aheadofprint
Résumé
SARS-CoV-2 seroprevalence reflects the efficacy of pandemic infection prevention and control measures. We performed anti-spike IgG serological testing on residual sera of children 1-11 years old at a tertiary care referral center between October and November 2021. Immunocompromised patients had the highest SARS-CoV-2 seroprevalence, at 40.5%, compared to 19.3% in non-immunocompromised patients. Targeted infection prevention and public health interventions are warranted for pediatric immunocompromised patients in future pandemics.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31365Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Connelly JA, Chong H, Esbenshade AJ, et al. Impact of COVID‐19 on pediatric immunocompromised patients. Pediatr Clin N Am. 2021;68(5):1029‐1054.
Freeman MC, Rapsinski GJ, Zilla ML, Wheeler SE. Immunocompromised seroprevalence and course of illness of SARS‐CoV‐2 in one pediatric quaternary care center. J Pediatr Infect Dis Soc. 2021;10(4):426‐431.
Sundberg E, Hoffman T, Nilsson A, et al. COVID‐19 seroprevalence and clinical picture in pediatric oncology and hematology patients. Pediatr Blood Cancer. 2022;69(10):e29773.
Anti‐SARS‐CoV‐2S1 Curve ELISA (IgG) instructions for use. FDA; Published 2022. Accessed July 29, 2024. https://www.fda.gov/media/152747/download
COVID‐19 vaccine bookings to open for all children aged five to 11. Ontario Newsroom; Published 2021. Accessed July 29, 2024. https://news.ontario.ca/en/release/1001195/covid‐19‐vaccine‐bookings‐to‐open‐for‐all‐children‐aged‐five‐to‐11
Science M, Bolotin S, Silverman M, et al. SARS‐CoV‐2 antibodies in Ontario health care workers during and after the first wave of the pandemic: a cohort study. CMAJ Open. 2021;9(4):e929‐e939.
Mark C, Gibson P, Lafay‐Cousin L, et al. Outcomes of coronavirus disease 2019 infection in children and adolescents with cancer in Canada: population‐based study and systematic review. J Pediatr Hematol Oncol. 2023;45(6):e689‐e694.
Ilinca AP, Dakhallah N, Souza AM, et al. Clinical characteristics and outcomes of SARS‐CoV‐2 infection in pediatric oncology patients in the province of Quebec. Pediatr Blood Cancer. 2022;69(4):e29572.
Schober T, Caya C, Barton M, et al. Risk factors for severe PCR‐positive SARS‐CoV‐2 infection in hospitalised children. BMJ Paediatr Open. 2022;6(1):e001440.
Sundberg E, Georgantzi K, Langenskiold C, et al. Low numbers of COVID‐19 in Swedish pediatric oncology patients during the first pandemic year despite an open society. Pediatr Blood Cancer. 2022;69(10):e29750.
Weclawek‐Tompol J, Zakrzewska Z, Gryniewicz‐Kwiatkowska O, et al. COVID‐19 in pediatric cancer patients is associated with treatment interruptions but not with short‐term mortality: a Polish national study. J Hematol Oncol. 2021;14(1):163.
Hashmi SK, Bodea J, Patni T, et al. COVID‐19 in pediatric patients with acute lymphoblastic leukemia or lymphoma. JAMA Netw Open. 2024;7(2):e2355727.
Ruiz J, Aldewereld Z, Elgarten C. Chemotherapy delays due to SARS‐CoV‐2 infection in children with leukemia or lymphoma. JAMA Netw Open. 2024;7(2):e2355679.
Gorochov G, Ropers J, Launay O, et al. Serum and salivary IgG and IgA response after COVID‐19 messenger RNA vaccination. JAMA Netw Open. 2024;7(4):e248051.